Quanta Inc (fka QNTA)

[shoondale]

Thank you Dragon Lady for the most substantial review of the conference call. This expensive trip undoubtedly is taking place on shareholder dime. If Mikaelian is focusing on research it begs the question of how this benefits and furthers revenues, If Farmastevsik is moving product for Quanta, why has it not shown up in revenues?

It is disturbing that the lack of questions of this nature are lacking from shareholders who need to protect their investment. Where is the concern?

This trip offhand seems extravagantly expensive with the massive dilution than has occurred this year. Who is looking out for shareholders? How does this trip benefit sharteholdrs?